Abcellera Biologics Inc
NASDAQ:ABCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Abcellera Biologics Inc
Operating Expenses
Abcellera Biologics Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Operating Expenses
-$292.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Operating Expenses
-CA$39.4k
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Operating Expenses
-CA$2.4m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-15%
|
|
Abcellera Biologics Inc
Glance View
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. AbCellera's full-stack, artificial intelligence (AI)-powered drug discovery platform integrates technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.
See Also
What is Abcellera Biologics Inc's Operating Expenses?
Operating Expenses
-292.2m
USD
Based on the financial report for Dec 31, 2025, Abcellera Biologics Inc's Operating Expenses amounts to -292.2m USD.
What is Abcellera Biologics Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-31%
Over the last year, the Operating Expenses growth was 15%. The average annual Operating Expenses growth rates for Abcellera Biologics Inc have been -3% over the past three years , -31% over the past five years .
